|
1
|
Zhang L, Zhong DX, Yue M, Xuan LT, Zhang ZX, Li JJ, Li JH, Zou JZ, Yan YC, Liu R. [Clinical analysis of six cases of mucormycosis in children with acute leukemia]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:594-597. [PMID: 37749043 PMCID: PMC10509617 DOI: 10.3760/cma.j.issn.0253-2727.2023.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Indexed: 09/27/2023]
Affiliation(s)
- L Zhang
- Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China
| | - D X Zhong
- Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China
| | - M Yue
- Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China
| | - L T Xuan
- Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China
| | - Z X Zhang
- Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China
| | - J J Li
- Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China
| | - J H Li
- Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China
| | - J Z Zou
- Department of Pathology, Capital Institute of Pediatrics, Beijing 100020, China
| | - Y C Yan
- Department of Imaging, Capital Institute of Pediatrics, Beijing 100020, China
| | - R Liu
- Department of Hematology, Capital Institute of Pediatrics, Beijing 100020, China
| |
Collapse
|
|
2
|
Zhong DX, Zhang Y, Jin Q, Zhang XC, Zhang F, Chen DD, Guan LH, Zhou DX, Ge JB. Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines. Pulm Circ 2021; 11:20458940211051292. [PMID: 34659741 PMCID: PMC8516391 DOI: 10.1177/20458940211051292] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2021] [Accepted: 09/20/2021] [Indexed: 12/14/2022] Open
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important and major player in the pathophysiology of hypercholesterolemia and atherosclerosis. Recently, PCSK9 has been implicated in the pathogenesis of inflammatory diseases. Whether PCSK9 is involved in idiopathic pulmonary arterial hypertension (IPAH) remains unclear. This study aimed to investigate the relationship between PCSK9 and IPAH. Serum PCSK9, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1β), and monocyte chemotactic protein-1 (MCP-1) were measured by enzyme linked immunosorbent assay. Transthoracic echocardiography was performed among 40 IPAH patients and 20 control subjects. Hemodynamic data were collected via right heart catheterization in patients with IPAH. Serum PCSK9, TNF-α, IL-6, IL-1β, and MCP-1 levels were significantly higher in IPAH patients than in control subjects (p < 0.001). Among enrolled IPAH patients, PCSK9 levels were higher in WHO-FC III/IV patients compared with those in WHO-FC I/II (p < 0.05), and were positively correlated with TNF-α, IL-6, MCP-1, N-Terminal pro-brain natriuretic peptide, pulmonary arterial systolic pressure (r = 0.653, p < 0.001), pulmonary arterial diastolic pressure (r = 0.466, p = 0.002), mean pulmonary arterial pressure (mPAP, r = 0.730, <0.001), pulmonary vascular resistance (r = 0.488, p = 0.001), and right ventricle diameter (r = 0.563, p < 0.001). In multiple regression analysis, mPAP was strongly associated with serum PCSK9 (β = 0.694, p < 0.001), independent of other variables. Receiver operating characteristic curve analysis showed the optimal cutoff value of serum PCSK9 concentration for predicting IPAH was 90.67 ng/ml, with a sensitivity of 90.0% and a specificity of 85.0%. In conclusion, IPAH patients had elevated serum PCSK9 levels which correlated the presence and severity of pulmonary hypertension. PCSK9 may be a novel potential therapeutic target.
Collapse
Affiliation(s)
- Dong-Xiang Zhong
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Yuan Zhang
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Qi Jin
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Xiao-Chun Zhang
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Feng Zhang
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Dan-Dan Chen
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Li-Hua Guan
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Da-Xin Zhou
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Jun-Bo Ge
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
| |
Collapse
|